MedTrace Logo

Effectiveness of Sugammadex in LMS Surgery

NCT02329964 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-09-28

Study results available
· View outcomes & findings →

Summary

This study is comparing of rocuronium-sugammadex and succinylcholine during LMS surgery that is characterized by short operation time, required intense paralysis and ambulatory setting, has not been investigated.

Conditions

  • Muscle Relaxation

Interventions

DRUG

Sugammadex

Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.

DRUG

Neostigmine

Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.

Sponsors & Collaborators

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Jangeun Cho, M.D.,Ph.D. · Anesthesia and pain medicine department, Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-08-31
Completion
2016-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329964 on ClinicalTrials.gov